Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?

被引:12
作者
Delavenne, X. [1 ,2 ,3 ]
Mallouk, N. [2 ,3 ]
Piot, M. [2 ,3 ]
Mismetti, P. [2 ,3 ,4 ]
Laporte, S. [2 ,3 ,4 ]
机构
[1] CHU St Etienne, Lab Pharmacol Toxicol, St Etienne, France
[2] Univ Lyon, St Etienne, France
[3] Univ St Etienne, Grp Rech Thrombose, St Etienne, France
[4] CHU St Etienne, Unite Rech Clin Innovat & Pharmacol, St Etienne, France
关键词
PERCUTANEOUS CORONARY INTERVENTION; LC-MS/MS; RESPONSIVENESS; METAANALYSIS; ASSOCIATION; INHIBITION; ASPIRIN;
D O I
10.1111/j.1538-7836.2010.04004.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2334 / 2338
页数:5
相关论文
共 26 条
[21]   Clopidogrel non responsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis [J].
Snoep, Jaapjan D. ;
Hovens, Marcel M. C. ;
Eikenboom, Jeroen C. J. ;
van der Bom, Johanna G. ;
Jukema, J. Wouter ;
Huisman, Menno V. .
AMERICAN HEART JOURNAL, 2007, 154 (02) :221-231
[22]   Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS [J].
Takahashi, Makoto ;
Pang, Henrianna ;
Kawabata, Kiyoshi ;
Farid, Nagy A. ;
Kurihara, Atsushi .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (04) :1219-1224
[23]   Pharmacokinetics of clopidogrel after administration of a high loading dose [J].
Taubert, D ;
Kastrati, A ;
Harlfinger, S ;
Gorchakova, O ;
Lazar, A ;
von Beckerath, N ;
Schömig, A ;
Schömig, E .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (02) :311-316
[24]   Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease [J].
Wallentin, Lars ;
Varenhorst, Christoph ;
James, Stefan ;
Erlinge, David ;
Braun, Oscar Oe ;
Jakubowski, Joseph A. ;
Sugidachi, Atsuhiro ;
Winters, Kenneth J. ;
Siegbahn, Agneta .
EUROPEAN HEART JOURNAL, 2008, 29 (01) :21-30
[25]   P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use [J].
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2009, 30 (16) :1964-1977
[26]  
PLAVIC CLOPIDOGREL B